TD Cowen Lowers Axon Enterprise (NASDAQ:AXON) Price Target to $825.00

Axon Enterprise (NASDAQ:AXON) had its price objective decreased by stock analysts at TD Cowen from $950.00 to $825.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s target price suggests a potential upside of 134.82% from the company’s current price.

AXON has been the subject of a number of other research reports. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. Piper Sandler lowered their target price on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a report on Tuesday, January 6th. Royal Bank Of Canada lowered their target price on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a report on Wednesday, February 25th. Finally, UBS Group lowered their target price on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $755.88.

Axon Enterprise Price Performance

AXON stock opened at $351.33 on Wednesday. The stock has a 50-day moving average price of $467.16 and a two-hundred day moving average price of $569.82. The stock has a market cap of $28.25 billion, a PE ratio of 231.14, a price-to-earnings-growth ratio of 8.36 and a beta of 1.61. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. Axon Enterprise has a 1 year low of $347.28 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The firm had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The company’s revenue was up 38.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.08 EPS. Equities analysts forecast that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CAO Jennifer H. Mak sold 1,500 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the transaction, the chief accounting officer owned 12,240 shares in the company, valued at $7,019,028. This trade represents a 10.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the transaction, the insider owned 55,588 shares of the company’s stock, valued at $29,740,135.88. The trade was a 3.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,855 shares of company stock worth $7,109,828 over the last three months. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds have recently modified their holdings of the stock. Newbridge Financial Services Group Inc. grew its holdings in shares of Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 14 shares in the last quarter. Vicus Capital grew its holdings in Axon Enterprise by 3.7% during the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 14 shares during the period. Evergreen Capital Management LLC grew its holdings in Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares during the period. Blue Trust Inc. grew its holdings in Axon Enterprise by 2.5% during the third quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 16 shares during the period. Finally, NorthCrest Asset Manangement LLC grew its holdings in Axon Enterprise by 5.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 16 shares during the period. Institutional investors own 79.08% of the company’s stock.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Wall Street reaffirmations and bullish notes tied to Axon Week and new AI products have supported the stock recently; several analysts reiterated buy ratings and highlighted AI-driven growth as a reason to view the pullback as a buying opportunity. Why Axon Stock Bounced Back After Falling 10%
• Positive Sentiment: Axon unveiled new AI offerings (Axon Vision, expanded Axon Assistant, Axon 911) at its annual conference intended to boost real-time public-safety data capabilities — a product roadmap that analysts say could drive multi-year revenue and margin improvement. Can Axon’s New AI Suite Reframe Its Real-Time Data Advantage Story for Investors (AXON)?
• Neutral Sentiment: Analysts trimmed price targets (Goldman Sachs and TD Cowen cut targets) but largely maintained constructive ratings — this reduces upside in the near term while leaving longer-term bull cases intact. Goldman Sachs price target update
• Neutral Sentiment: Sector/market news (e.g., coverage of peers and ad-tech moves) may be pulling investor attention and flows away from defensible growth stories, but these items are indirect for Axon. Macquarie sees AppLovin’s e-commerce push as a multi-year growth driver
• Negative Sentiment: New legal risk headlines tied to the company’s HQ and the cumulative effect of price-target cuts triggered fresh selling pressure; those headlines were cited by market coverage as a primary reason shares moved lower. Why Axon (AXON) Shares Are Trading Lower Today
• Negative Sentiment: Today’s decline was compounded by momentum selling and elevated volume after yesterday’s drop; market commentary and drop reports amplified the move. Axon Enterprise (AXON) Stock Drops Despite Market Gains

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.